HK1206634A1 - Vehicles for controlled delivery of different pharmaceutical agents - Google Patents
Vehicles for controlled delivery of different pharmaceutical agentsInfo
- Publication number
- HK1206634A1 HK1206634A1 HK15107374.4A HK15107374A HK1206634A1 HK 1206634 A1 HK1206634 A1 HK 1206634A1 HK 15107374 A HK15107374 A HK 15107374A HK 1206634 A1 HK1206634 A1 HK 1206634A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vehicles
- pharmaceutical agents
- controlled delivery
- different pharmaceutical
- different
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261623486P | 2012-04-12 | 2012-04-12 | |
US201261747614P | 2012-12-31 | 2012-12-31 | |
US201261747624P | 2012-12-31 | 2012-12-31 | |
PCT/US2013/036487 WO2013155487A1 (en) | 2012-04-12 | 2013-04-12 | Vehicles for controlled delivery of different pharmaceutical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206634A1 true HK1206634A1 (en) | 2016-01-15 |
Family
ID=48184518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107374.4A HK1206634A1 (en) | 2012-04-12 | 2015-07-31 | Vehicles for controlled delivery of different pharmaceutical agents |
Country Status (8)
Country | Link |
---|---|
US (9) | US9603800B2 (xx) |
EP (3) | EP3939572B1 (xx) |
JP (5) | JP6378170B2 (xx) |
CA (1) | CA2869748C (xx) |
ES (1) | ES2745211T3 (xx) |
HK (1) | HK1206634A1 (xx) |
PL (1) | PL2836234T3 (xx) |
WO (2) | WO2013155487A1 (xx) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9475709B2 (en) | 2010-08-25 | 2016-10-25 | Lockheed Martin Corporation | Perforated graphene deionization or desalination |
DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
WO2013155487A1 (en) | 2012-04-12 | 2013-10-17 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
WO2013163176A1 (en) | 2012-04-23 | 2013-10-31 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US9834809B2 (en) | 2014-02-28 | 2017-12-05 | Lockheed Martin Corporation | Syringe for obtaining nano-sized materials for selective assays and related methods of use |
US9744617B2 (en) | 2014-01-31 | 2017-08-29 | Lockheed Martin Corporation | Methods for perforating multi-layer graphene through ion bombardment |
US9610546B2 (en) | 2014-03-12 | 2017-04-04 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene and methods for use thereof |
US10653824B2 (en) | 2012-05-25 | 2020-05-19 | Lockheed Martin Corporation | Two-dimensional materials and uses thereof |
CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
BR112015016420B1 (pt) * | 2013-01-08 | 2022-12-06 | Idera Pharmaceuticals, Inc | Composto de oligonucleotídeo imunorregulatório, composição farmacêutica e uso do composto iro ou da composição farmacêutica |
EP2968584A1 (en) * | 2013-03-11 | 2016-01-20 | Cristal Delivery B.V. | Vaccination composition |
US9592475B2 (en) | 2013-03-12 | 2017-03-14 | Lockheed Martin Corporation | Method for forming perforated graphene with uniform aperture size |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CN105188741A (zh) | 2013-04-03 | 2015-12-23 | 阿勒丁医疗公司 | 新型纳米颗粒组合物 |
US9572918B2 (en) | 2013-06-21 | 2017-02-21 | Lockheed Martin Corporation | Graphene-based filter for isolating a substance from blood |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN105848649B (zh) * | 2013-11-01 | 2019-08-02 | 耶鲁大学 | 用于免疫疗法的模块化粒子 |
CA2938273A1 (en) | 2014-01-31 | 2015-08-06 | Peter V. Bedworth | Perforating two-dimensional materials using broad ion field |
JP2017507044A (ja) | 2014-01-31 | 2017-03-16 | ロッキード マーティン コーポレイションLockheed Martin Corporation | 多孔性非犠牲支持層を用いた二次元材料とのコンポジット構造を形成するための方法 |
JP2017512129A (ja) | 2014-03-12 | 2017-05-18 | ロッキード・マーチン・コーポレーション | 有孔グラフェンから形成された分離膜 |
WO2015140150A1 (en) * | 2014-03-17 | 2015-09-24 | Piotr Jachimczak | Combination for use in a method of treating cancer |
WO2015148512A1 (en) | 2014-03-24 | 2015-10-01 | Qt Holdings Corp | Shaped articles including hydrogels and methods of manufacture and use thereof |
US9956176B2 (en) | 2014-04-01 | 2018-05-01 | Children's Hospital Los Angeles | Compositions and methods for treating ewing sarcoma |
EP3129062A4 (en) * | 2014-04-01 | 2017-11-29 | Children's Hospital Los Angeles | Targeted polymerized nanoparticles for cancer treatment |
EP3148552B1 (en) | 2014-05-30 | 2019-07-31 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
KR20170095804A (ko) | 2014-09-02 | 2017-08-23 | 록히드 마틴 코포레이션 | 이차원 막 소재에 기반을 둔 혈액 투석 및 혈액 여과 막과 이를 이용하는 방법 |
WO2016123229A1 (en) * | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
CN104735414B (zh) * | 2015-03-25 | 2017-11-28 | 江苏物联网研究发展中心 | 面向视频监控系统的半实物仿真方法 |
JP6522387B2 (ja) * | 2015-03-27 | 2019-05-29 | 株式会社キレートジャパン | ハイドロゲル含有化粧料 |
WO2016168197A1 (en) | 2015-04-15 | 2016-10-20 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
AU2016281685B2 (en) | 2015-06-24 | 2021-08-12 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
AU2016303048A1 (en) | 2015-08-05 | 2018-03-01 | Lockheed Martin Corporation | Perforatable sheets of graphene-based material |
MX2018001559A (es) | 2015-08-06 | 2018-09-27 | Lockheed Corp | Modificacion de nanoparticula y perforacion de grafeno. |
US10626469B2 (en) | 2015-09-04 | 2020-04-21 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Rapid identification of microorganisms |
RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
US9790467B2 (en) | 2015-09-22 | 2017-10-17 | Qt Holdings Corp | Methods and compositions for activation or expansion of T lymphocytes |
JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
JP2019511451A (ja) | 2016-04-14 | 2019-04-25 | ロッキード・マーチン・コーポレーション | 浮遊法を用いてグラフェンシートを大判転写用に処理する方法 |
KR20190018411A (ko) | 2016-04-14 | 2019-02-22 | 록히드 마틴 코포레이션 | 그래핀 결함의 선택적 계면 완화 |
KR20180133430A (ko) | 2016-04-14 | 2018-12-14 | 록히드 마틴 코포레이션 | 결함 형성 또는 힐링의 인 시츄 모니터링 및 제어를 위한 방법 |
JP2019517909A (ja) | 2016-04-14 | 2019-06-27 | ロッキード・マーチン・コーポレーション | 流路を有する二次元膜構造体 |
WO2017180134A1 (en) | 2016-04-14 | 2017-10-19 | Lockheed Martin Corporation | Methods for in vivo and in vitro use of graphene and other two-dimensional materials |
WO2017180135A1 (en) | 2016-04-14 | 2017-10-19 | Lockheed Martin Corporation | Membranes with tunable selectivity |
JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
EP3251662A1 (en) * | 2016-06-07 | 2017-12-06 | Tolerogenics S.à.r.l. | Matrix-embedded tolerance-promotion adjuvants for subcutaneous immunotherapy |
CN109476841B (zh) * | 2016-07-30 | 2021-08-24 | 日本化药株式会社 | 新型高分子衍生物和使用其的新型高分子衍生物成像探针 |
WO2018051298A1 (en) * | 2016-09-19 | 2018-03-22 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
EP3534909A4 (en) * | 2016-11-02 | 2020-06-03 | Nanoproteagen | POLYMANANOPARTICLE |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
ES2968358T3 (es) * | 2016-12-26 | 2024-05-09 | Fujifilm Corp | Composición de partículas lipídicas y composición farmacéutica |
JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
SG11201907916TA (en) | 2017-03-15 | 2019-09-27 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
WO2018170398A1 (en) | 2017-03-16 | 2018-09-20 | Children's Medical Center Corporation | Engineered liposomes as cancer-targeted therapeutics |
US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
JP6482604B2 (ja) * | 2017-06-22 | 2019-03-13 | 教裕 南郷 | 外皮内溶解型ニードル及びニードル装置 |
WO2019005966A1 (en) | 2017-06-29 | 2019-01-03 | Massachusetts Institute Of Technology | CONJUGATED DRUG DENDRIMER FOR EXTENDED INTRA-ARTICULAR ADMINISTRATION |
US11554178B2 (en) | 2017-06-30 | 2023-01-17 | City Of Hope | Compositions and methods of modulating macrophage activity |
EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US20200246484A1 (en) * | 2017-10-03 | 2020-08-06 | Northwestern University | Spherical nucleic acids (snas) with sheddable peg layers |
CN111278477A (zh) * | 2017-10-25 | 2020-06-12 | 精密医疗国际公司 | 生物降解性和生物代谢性的肿瘤封闭剂 |
WO2019109980A1 (zh) * | 2017-12-06 | 2019-06-13 | 科济生物医药(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
KR102153535B1 (ko) * | 2018-03-30 | 2020-09-08 | 한국과학기술원 | 동맥경화증 치료를 위한 화물치환 분해성 나노바이오소재 |
US11517628B2 (en) * | 2018-05-09 | 2022-12-06 | Yale University | Particles for spatiotemporal release of agents |
WO2020014208A1 (en) | 2018-07-09 | 2020-01-16 | Yale University | Camk4 inhibitors for restoration of podocyte function in kidney disease |
US11680243B2 (en) * | 2019-02-20 | 2023-06-20 | Iowa State University Research Foundation, Inc. | Conductive graphene matrix-encapsulated cells |
CN110393700A (zh) * | 2019-04-02 | 2019-11-01 | 武汉理工大学 | F3多肽导向的pamam为核心的肿瘤药物纳米载体的制备与应用 |
US20220249696A1 (en) * | 2019-04-12 | 2022-08-11 | The Johns Hopkins University | Tolerogenic artificial antigen-presenting cells |
CN109916896A (zh) * | 2019-04-12 | 2019-06-21 | 吉林省汇酉生物技术股份有限公司 | 一种定量检测血红蛋白含量的干化学试剂片及其制备方法 |
US20220211683A1 (en) * | 2019-05-09 | 2022-07-07 | The University Of Chicago | Novel material for skin wound closure and scar prevention |
EP3986379A1 (en) * | 2019-06-19 | 2022-04-27 | Becton, Dickinson and Company | Biodegradable drug-eluting embolic particles for delivery of therapeutic agents |
WO2021055833A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
US20220395563A1 (en) * | 2019-11-11 | 2022-12-15 | The Regents Of The University Of California | Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance |
IL293607A (en) * | 2019-12-05 | 2022-08-01 | Univ West Virginia | protein-loaded plga nanospheres |
CN111450094A (zh) * | 2020-05-06 | 2020-07-28 | 南开大学 | 一种TGF-beta受体分子抑制剂在癌基因KrasG12D突变的胰腺癌治疗中的应用 |
CN114108177B (zh) * | 2020-08-28 | 2022-12-27 | 北京化工大学 | 一种可光热触发生长因子阶段性释放的人工皮肤材料及其制法和应用 |
IT202100002537A1 (it) * | 2021-02-05 | 2022-08-05 | Kyme Nanoimaging Srl | Processo microfluidico per la preparazione di nanostrutture liposomiche caricate con idrogel |
CN113908138A (zh) * | 2021-09-08 | 2022-01-11 | 四川大学华西医院 | 一种神经胶质瘤抗体药物组合物及制备方法 |
WO2023062353A1 (en) * | 2021-10-11 | 2023-04-20 | Newimmune Ii, Llc | Nanoparticulate formulation |
GB202201351D0 (en) | 2022-02-02 | 2022-03-16 | Activate Therapeutics Llc | Nanoparticulate formulation |
CN113926427A (zh) * | 2021-10-16 | 2022-01-14 | 西安绿碳资源循环科技有限公司 | 一种用于捕集空气中二氧化碳的改性石墨烯膜及其制备方法 |
WO2023129822A2 (en) * | 2021-12-28 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified bacterial peptidoglycan compositions and uses thereof |
KR102626722B1 (ko) * | 2022-08-04 | 2024-01-22 | 서울대학교산학협력단 | 나노카테난 구조체 및 나노카테난 구조체를 포함하는 나노머신 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US5210079A (en) | 1988-01-07 | 1993-05-11 | E. I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists |
US5354867A (en) | 1988-12-06 | 1994-10-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
ES2148224T3 (es) | 1992-03-30 | 2000-10-16 | American Home Prod | Formulacion de rapamicina para inyecciones intravenosas. |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
WO1995015746A1 (en) | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
SG64372A1 (en) | 1993-12-17 | 1999-04-27 | Novartis Ag | Rapamycin derivatives |
US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
GB9814640D0 (en) | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
US7426492B1 (en) | 1999-11-05 | 2008-09-16 | American Express Travel Related Services Company, Inc. | Systems and methods for facilitating commercial transactions between parties residing at remote locations |
US7943067B2 (en) * | 2001-08-16 | 2011-05-17 | Polytechnic Institute Of New York University | Nanogels and their production using liposomes as reactors |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
FR2849040A1 (fr) | 2002-12-18 | 2004-06-25 | Arandi Pharma | Polypeptides a activite antivirale |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
US20060099203A1 (en) | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
CN104436190A (zh) | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
US20070243184A1 (en) | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
EP1966765A2 (en) | 2005-12-20 | 2008-09-10 | Philips Intellectual Property & Standards GmbH | Method for movement compensation of image data |
JP2008053276A (ja) | 2006-08-22 | 2008-03-06 | Nec Electronics Corp | 半導体装置の製造方法 |
NZ578650A (en) | 2006-12-27 | 2011-12-22 | Harvard College | Pd-1 and activated t-cell compositions and methods for the treatment of viral infections and tumors |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
EP2177230A4 (en) * | 2007-08-09 | 2011-04-27 | Daiichi Sankyo Co Ltd | IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL |
BRPI0818963A2 (pt) | 2007-11-30 | 2015-05-05 | Bristol Myers Squibb Co | Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
WO2010083337A2 (en) | 2009-01-15 | 2010-07-22 | The Regents Of The University Of Califorinia | Composite nanostructures and methods for making and using them |
CA2776925C (en) | 2009-10-26 | 2018-07-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
WO2011133803A1 (en) | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions and methods for targeted inactivation of hiv cell surface receptors |
US20110293690A1 (en) | 2010-05-27 | 2011-12-01 | Tyco Healthcare Group Lp | Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof |
WO2012009611A2 (en) | 2010-07-16 | 2012-01-19 | The Johns Hopkins University | Methods and compositions for cancer immunotherapy |
JP2014505666A (ja) | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
WO2013086365A2 (en) | 2011-12-09 | 2013-06-13 | Metabolon, Inc. | Biomarkers for kidney cancer and methods using the same |
WO2013155487A1 (en) * | 2012-04-12 | 2013-10-17 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
CN105848649B (zh) | 2013-11-01 | 2019-08-02 | 耶鲁大学 | 用于免疫疗法的模块化粒子 |
-
2013
- 2013-04-12 WO PCT/US2013/036487 patent/WO2013155487A1/en active Application Filing
- 2013-04-12 EP EP21192661.3A patent/EP3939572B1/en active Active
- 2013-04-12 WO PCT/US2013/036494 patent/WO2013155493A1/en active Application Filing
- 2013-04-12 JP JP2015505965A patent/JP6378170B2/ja active Active
- 2013-04-12 CA CA2869748A patent/CA2869748C/en active Active
- 2013-04-12 US US14/394,147 patent/US9603800B2/en active Active
- 2013-04-12 EP EP19161397.5A patent/EP3520780B1/en active Active
- 2013-04-12 EP EP13718738.1A patent/EP2836234B1/en active Active
- 2013-04-12 PL PL13718738T patent/PL2836234T3/pl unknown
- 2013-04-12 ES ES13718738T patent/ES2745211T3/es active Active
- 2013-04-12 US US14/394,161 patent/US9610250B2/en active Active
-
2015
- 2015-07-31 HK HK15107374.4A patent/HK1206634A1/xx unknown
-
2016
- 2016-05-15 US US15/155,055 patent/US10034917B2/en active Active
-
2017
- 2017-02-16 US US15/434,971 patent/US10195144B2/en active Active
-
2018
- 2018-03-16 US US15/923,139 patent/US10603276B2/en active Active
- 2018-05-07 JP JP2018089170A patent/JP6608996B2/ja active Active
- 2018-06-27 US US16/019,704 patent/US10500157B2/en active Active
-
2019
- 2019-01-03 US US16/238,683 patent/US10709664B2/en active Active
- 2019-08-22 JP JP2019152051A patent/JP2019196410A/ja not_active Withdrawn
- 2019-12-12 US US16/711,591 patent/US11173119B2/en active Active
-
2021
- 2021-06-18 JP JP2021101463A patent/JP2021138771A/ja not_active Withdrawn
- 2021-08-11 US US17/399,544 patent/US20220031617A1/en active Pending
- 2021-10-22 JP JP2021172984A patent/JP7291967B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206634A1 (en) | Vehicles for controlled delivery of different pharmaceutical agents | |
HK1258394A1 (zh) | 治療劑傳遞 | |
HK1209021A1 (en) | Nanotherapeutics for drug targeting | |
HK1208374A1 (en) | Biodegradable drug delivery for hydrophobic compositions | |
HK1205928A1 (en) | Ocular drug delivery system | |
HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
HK1205010A1 (en) | System for delivering medication | |
ZA201502352B (en) | Liposomal drug delivery system | |
SG11201401851UA (en) | Methods for drug delivery | |
EP2849770A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS | |
HRP20190050T1 (hr) | Farmaceutski pripravci za kombinacijsku terapiju | |
EP2776091A4 (en) | METHODS FOR DELIVERY OF VISCOUS MEDICINAL TREATMENTS | |
GB201202091D0 (en) | Drug delivery apparatus | |
EP2921152A4 (en) | DRUG DELIVERY SYSTEM | |
HK1204258A1 (en) | Drug dispensing system | |
HK1210271A1 (en) | Ophthalmic devices for delivery of beneficial agents | |
IL229425A0 (en) | Controlled release drug administration preparations | |
PL2908837T3 (pl) | Kompozycje do dostarczania leku | |
EP2917860A4 (en) | MEDICINES SUPPLY SYSTEM | |
EP2852378A4 (en) | COPOLYMER-XEROGEL NANOCOMPOSITES USEFUL FOR THE ADMINISTRATION OF MEDICAMENTS | |
EP2896401A4 (en) | TARGETED ACTIVE AGGREGATION SYSTEM FOR HEAVY-DUTY ACTIVE SUBSTANCE | |
ZA201306823B (en) | Excipient system for topical delivery of pharmaceutical agents | |
PT2814473T (pt) | Composições farmacêuticas para terapia de combinação |